Journal article
Economic Evaluation of Bevacizumab for Treatment of Platinum-Resistant Recurrent Ovarian Cancer in Canada
Abstract
BackgroundOvarian cancer is a leading cause of cancer-related mortality. Although the disease is relatively rare, it carries a disproportionately large morbidity burden.ObjectiveWe conducted a cost-utility analysis from a Canadian public payer perspective to determine the cost effectiveness of bevacizumab, a newly available treatment option for recurrent ovarian cancer.MethodsUsing a 7-year time horizon, a three health-state cohort-based …
Authors
Ball G; Xie F; Tarride J-E
Journal
PharmacoEconomics - Open, Vol. 2, No. 1, pp. 19–29
Publisher
Springer Nature
Publication Date
March 2018
DOI
10.1007/s41669-017-0030-7
ISSN
2509-4262